C2C12 myoblast-to-myotube differentiation
Materials Required
Principle
C2C12 cells are mouse myoblast-lineage cells that proliferate in growth conditions and differentiate after mitogen reduction into elongated, multinucleated myotubes; the differentiation readout is generated by morphology, myogenic marker expression, and immunofluorescent detection of myosin heavy chain-positive myotubes with nuclear counterstaining[1][2][3][4].
MCE has not independently verified the accuracy of these methods. They are for reference only.
Experimental Materials
• Use C2C12 cells, DMEM-based growth medium with fetal bovine serum for expansion, and low-serum differentiation medium based on DMEM with horse serum; published studies report induction at about 80-90% confluence and commonly use 2% horse serum, while one morpho-functional study used 1% fetal calf serum after about 80% confluence[3][5][6].
• Use PBS for washing, paraformaldehyde for fixation, Triton X-100 for permeabilization, and serum/BSA-containing blocking solution when immunofluorescence is used to visualize myogenic differentiation[3][4].
• Use antibodies against myosin heavy chain or sarcomeric myosin to identify differentiated myocytes/myotubes, DAPI or another DNA stain to count nuclei, and optional antibodies or assays for MyoD, myogenin, sarcomeric actin, M-cadherin, or creatine kinase when marker-level confirmation is required[2][3][4][7].
• Use a humidified 37 °C, 5% CO2 incubator, tissue-culture vessels, an inverted phase-contrast microscope for morphology, and a fluorescence or confocal microscope for MyHC/DAPI-based differentiation and fusion analysis[3][4][5].
• Use PBS for washing, paraformaldehyde for fixation, Triton X-100 for permeabilization, and serum/BSA-containing blocking solution when immunofluorescence is used to visualize myogenic differentiation[3][4].
• Use antibodies against myosin heavy chain or sarcomeric myosin to identify differentiated myocytes/myotubes, DAPI or another DNA stain to count nuclei, and optional antibodies or assays for MyoD, myogenin, sarcomeric actin, M-cadherin, or creatine kinase when marker-level confirmation is required[2][3][4][7].
• Use a humidified 37 °C, 5% CO2 incubator, tissue-culture vessels, an inverted phase-contrast microscope for morphology, and a fluorescence or confocal microscope for MyHC/DAPI-based differentiation and fusion analysis[3][4][5].
Experimental Procedure
• Maintain C2C12 cells under proliferative growth conditions until the culture reaches the confluence reported for differentiation induction, most commonly about 80-90%, then replace growth medium with differentiation medium rather than allowing the protocol to rely on unsupported timing alone[3][5][6].
• Prepare differentiation medium as DMEM containing low serum; reported serum conditions include 2% horse serum in several C2C12 differentiation studies and 1% fetal calf serum in a morpho-functional characterization study, so the selected condition should be kept constant within an experiment[3][5][6].
• Seed C2C12 cells so that they reach the selected induction confluence, document day 0 at the medium switch, replace growth medium with differentiation medium, and culture at 37 °C with 5% CO2; reported differentiation periods range from 48 h for early myotube appearance to 5-11 days for more developed multinucleated cultures depending on the study endpoint[3][5][6][8].
• Monitor morphology by phase-contrast microscopy during differentiation; expected changes include transition from fusiform or star-shaped myoblasts to elongated confluent cells and then long multinucleated myotubes, with sarcomeric actin/myosin organization and myofibrillar structures reported around later differentiation time points[3][8].
• For immunofluorescence endpoint analysis, wash cells with PBS, fix with paraformaldehyde, permeabilize with Triton X-100, block, stain with MyHC or sarcomeric myosin antibody plus nuclear dye, and image fields suitable for counting MyHC-positive cells and nuclei[3][4].
• Interpret successful differentiation as a combined increase in elongated multinucleated myotubes, MyHC-positive myotubes, and myogenic markers such as MyoD, myogenin, MyHC, sarcomeric actin, M-cadherin, or creatine kinase, depending on the chosen assay endpoint[2][3][4][7].
• Calculate differentiation index as the percentage of nuclei within MyHC-positive cells and fusion index as the percentage of nuclei within multinucleated MyHC-positive cells; one protocol recommends biological triplicates and counting 500-1,000 nuclei per replicate[4].
• Use undifferentiated growth-medium cultures as the baseline control and differentiation-medium cultures as the positive differentiation condition; when testing inhibitors or stressors, compare against matched differentiation-medium controls because LPS, myostatin, SB203580, and rapamycin have been reported to reduce myogenic differentiation or myotube formation in C2C12-related assays[7][9][10].
• Prepare differentiation medium as DMEM containing low serum; reported serum conditions include 2% horse serum in several C2C12 differentiation studies and 1% fetal calf serum in a morpho-functional characterization study, so the selected condition should be kept constant within an experiment[3][5][6].
• Seed C2C12 cells so that they reach the selected induction confluence, document day 0 at the medium switch, replace growth medium with differentiation medium, and culture at 37 °C with 5% CO2; reported differentiation periods range from 48 h for early myotube appearance to 5-11 days for more developed multinucleated cultures depending on the study endpoint[3][5][6][8].
• Monitor morphology by phase-contrast microscopy during differentiation; expected changes include transition from fusiform or star-shaped myoblasts to elongated confluent cells and then long multinucleated myotubes, with sarcomeric actin/myosin organization and myofibrillar structures reported around later differentiation time points[3][8].
• For immunofluorescence endpoint analysis, wash cells with PBS, fix with paraformaldehyde, permeabilize with Triton X-100, block, stain with MyHC or sarcomeric myosin antibody plus nuclear dye, and image fields suitable for counting MyHC-positive cells and nuclei[3][4].
• Interpret successful differentiation as a combined increase in elongated multinucleated myotubes, MyHC-positive myotubes, and myogenic markers such as MyoD, myogenin, MyHC, sarcomeric actin, M-cadherin, or creatine kinase, depending on the chosen assay endpoint[2][3][4][7].
• Calculate differentiation index as the percentage of nuclei within MyHC-positive cells and fusion index as the percentage of nuclei within multinucleated MyHC-positive cells; one protocol recommends biological triplicates and counting 500-1,000 nuclei per replicate[4].
• Use undifferentiated growth-medium cultures as the baseline control and differentiation-medium cultures as the positive differentiation condition; when testing inhibitors or stressors, compare against matched differentiation-medium controls because LPS, myostatin, SB203580, and rapamycin have been reported to reduce myogenic differentiation or myotube formation in C2C12-related assays[7][9][10].
Troubleshooting
Problem: Low MyHC-positive myotube formation.
• Possible Cause: insufficient activation of differentiation pathways.• Literature-supported Solution: verify that the cells were switched from growth medium to low-serum differentiation medium at the reported confluence range and avoid adding agents shown to inhibit differentiation, including myostatin, LPS, SB203580, or rapamycin, unless they are the experimental variable[5][7][9][10].
Problem: MyHC-positive cells are present but fusion is low.
• Possible Cause: differentiation and fusion can be separable readouts.• Literature-supported Solution: quantify both differentiation index and fusion index, because MyHC-positive status alone does not capture multinucleated myotube formation[2][4].
References:
- [1]. Yaffe D, et al. Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature. 1977;270(5639):725-727. [Content Brief]
- [2]. Andrés V, et al. Myogenin expression, cell cycle withdrawal, and phenotypic differentiation are temporally separable events that precede cell fusion upon myogenesis. J Cell Biol. 1996;132(4):657-666. [Content Brief]
- [3]. Burattini S, et al. C2C12 murine myoblasts as a model of skeletal muscle development: morpho-functional characterization. Eur J Histochem. 2004;48(3):223-233. [Content Brief]
- [4]. Asakura A. Immunofluorescence analysis of myogenic differentiation. Methods Cell Biol. 2022;169:1-20. [Content Brief]
- [5]. Pavlidou T, Rosina M, Fuoco C, Gerini G, Gargioli C, Castagnoli L, et al. Regulation of myoblast differentiation by metabolic perturbations induced by metformin. PLoS One. 2017;12(8):e0182475. [Content Brief]
- [6]. Hwang SY, Kang YJ, Sung B, Kim M, Kim DH, Lee Y, et al. Folic acid promotes the myogenic differentiation of C2C12 murine myoblasts through the Akt signaling pathway. Int J Mol Med. 2015;36(4):1073-1080. [Content Brief]
- [7]. Cuenda A, et al. Stress-activated protein kinase-2/p38 and a rapamycin-sensitive pathway are required for C2C12 myogenesis. J Biol Chem. 1999;274(7):4341-4346. [Content Brief]
- [8]. Janot M, et al. Glycogenome expression dynamics during mouse C2C12 myoblast differentiation suggests a sequential reorganization of membrane glycoconjugates. BMC Genomics. 2009;10:483. [Content Brief]
- [9]. Langley B, et al. Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. J Biol Chem. 2002;277(51):49831-49840. [Content Brief]
- [10]. Ono Y, et al. Lipopolysaccharide inhibits myogenic differentiation of C2C12 myoblasts through the Toll-like receptor 4-nuclear factor-κB signaling pathway and myoblast-derived tumor necrosis factor-α. PLoS One. 2017;12(7):e0182040. [Content Brief]
LinkedIn
Researchgate
Instagram
X
Facebook
WhatsApp
Reddit
Mail